ArticleChinese medical journal2016
Comparison of Talaromyces marneffei Infection in Human Immunodeficiency Virus-positive and Human Immunodeficiency Virus-negative Patients from Fujian, China.
Article in Chinese medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis.BMC infectious diseases · 2025Article
- COMMD1 Regulates Osteoclast Differentiation in Talaromyces marneffei-Induced Osteomyelitis via the NF-κB Pathway.Infection and drug resistance · 2025Article
- Machine learning-based high-specificity diagnostic model forFrontiers in microbiology · 2025Article
- Clinical and chest CT manifestations of Talaromycosis marneffei: a retrospective study comparing anti-IFN-γ autoantibodies-positive and HIV-positive cases.BMC infectious diseases · 2024Article
- Metagenomic Next-Generation Sequencing as an Effective Diagnostic Tool for Talaromycosis in HIV-Negative Patients.Mycopathologia · 2024Article
- Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.PLoS neglected tropical diseases · 2023Article
- Anticytokine Autoantibodies and Fungal Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal antibodies present in intravenous immunoglobulin derived from China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Anemia and opportunistic infections in hospitalized people living with HIV: a retrospective study.BMC infectious diseases · 2022Article
- HIV-child with disseminated Talaromyces Marneffei (Penicillium marneffei) infection: a rare severe case report.BMC pediatrics · 2022Article
- MALDI-TOF MS-Based Clustering and Antifungal Susceptibility Tests ofInfection and drug resistance · 2022Article
- HIV-negative case ofThe Journal of international medical research · 2021Article
- Characteristics ofAmerican journal of translational research · 2021Article
- Clinical characteristics and risk factors ofWorld journal of emergency medicine · 2021Article
- DisseminatedFrontiers in cellular and infection microbiology · 2021Article
- Rapid diagnosis ofIDCases · 2021Article
- Talaromyces marneffei Outside Endemic Areas in India: an Emerging Infection with Atypical Clinical Presentations and Review of Published Reports from India.Mycopathologia · 2020Article
- Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.Mycopathologia · 2019Review
- Characterization of Anti-Interferon-γ Antibodies in HIV-Negative Patients Infected With DisseminatedOpen forum infectious diseases · 2019Article
- Prevalence and risk factors of anaemia in hospitalised HIV-infected patients in southeast China: a retrospective study.Epidemiology and infection · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTalaromyces (Penicillium) marneffei (TM) is an emerging dimorphic human pathogenic fungus that is endemic to Southeast Asia. TM mostly occurs as an opportunistic infection in patients with human immunodeficiency virus (HIV). The objective of this study was to compare the clinical and laboratory parameters of patients with TM infections who were HIV-positive and HIV-negative and to assess therapies and outcomes.
methodsThis was a retrospective analysis of 26 patients diagnosed with disseminated TM infection from September 2005 to April 2014 at Fujian Provincial Hospital, China.
resultsPatients with TM infection tend to present with fever, weight loss, and anemia. The time from symptom onset to confirmed diagnosis was greater for HIV-negative patients (n = 7; median: 60 days, range: 14-365 days) than for HIV-positive patients (n = 19; median: 30 days, range: 3-90 days, Mann-Whitney U = 31.50, P= 0.041). HIV-negative patients were more likely to have dyspnea (57.1% vs. 5.3%, χ2 = 8.86, P= 0.010), low neutrophil count (Mann-Whitney U = 27.00, P= 0.029), high CD4 count (Mann-Whitney U = 0.00, P= 0.009), and high lymphocyte count (Mann-Whitney U = 21.00, P= 0.009). There were no significant differences in other demographic, clinical, or biochemical characteristics. Among all the patients, 12 HIV-positive patient and 1 HIV-negative patient received amphotericin and fluconazole treatment, 9 of whom improved, 1 died, 2 had kidney damage, 1 had hypokalemia due to exceeded doses.
conclusionsHIV-negative patients with TM infections tend to have a longer diagnostic interval, a higher percentage of dyspnea, higher levels of CD4 and lymphocytes, and lower neutrophil counts than TM infection in HIV-positive patients. Treatment programs with amphotericin and fluconazole are mostly effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.